Drug intelligence / Profile preview

123I-MNI-168

Development stage: Phase 1
Lead developer: Institute for Neurodegenerative Disorders
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

123I-MNI-168 is a diagnostic radiopharmaceutical developed for SPECT (Single-photon emission-computed tomography) imaging. It functions as an APP (Beta amyloid A4 protein) inhibitor and was designed to detect β-amyloid deposition in the brain. The drug was initially developed by the Institute for Neurodegenerative Disorders for potential use in Alzheimer's Disease diagnosis.

Other names: Iodine 123 MNI 168Iodine123 MNI 168Iodine-123 MNI 168[123I]MNI 168

Targets

Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on 123I-MNI-168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 123I-MNI-168.